semaglutide and naion use in patients with diabetes was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) at 2, 3, 4 years. https://ja.ma/4iZkMeV Summary of Study Findings on

2022A pilot clinical study to Evaluate liraglutide-mediated anti-platelet activity in patients with type-2 Diabetes (ELAID study)

As a unimolecular triple agonist, it targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors

A two-sided p-value of less than 0.05 was considered statistically significant

As ongoing research addresses current challenges, GLP-1RAs are poised to play a significant role in the future management of neurodegenerative and neuroinflammatory diseases

Will supplements interfere with my GLP-1 medication effectiveness

In two analyses, Noom members were modeled to gain less than 2% of bodyweight up to 12 months after stopping medication with the strongest maintenance among those who continued practicing healthy habits Noom members regained 3x less of their lost weight at 12 months than published post-discontinuation benchmarks (21.2% vs